Radiopharm Theranostics (RDPTF) Accounts Payables (2023 - 2026)

Radiopharm Theranostics (RDPTF) has reported Accounts Payables for 4 consecutive years, with $74707.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 24.88% year-over-year to $74707.7 in Q2 2026; TTM through Jun 2026 was $74707.7, a 24.88% increase from a year earlier, with the FY2026 full-year figure at $71527.8, down 99.23% from the prior year.
• Accounts Payables was $74707.7 for Q2 2026 at Radiopharm Theranostics, up from $59822.8 in the prior quarter.
• Over five years, Accounts Payables peaked at $7.3 million in Q4 2024 and troughed at $59822.8 in Q2 2025.
• A 4-year average of $2.5 million and a median of $74707.7 in 2026 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables plunged 98.6% in 2024 and advanced 24.88% in 2026, its largest moves.
• Over 4 years, Accounts Payables stood at $5.1 million in 2023, then surged by 43.19% to $7.3 million in 2024, then plunged by 99.18% to $59822.8 in 2025, then gained by 24.88% to $74707.7 in 2026.
• The last three Accounts Payables figures came in at $74707.7 (Q2 2026), $59822.8 (Q2 2025), and $7.3 million (Q4 2024), per Business Quant data.